Menu
PTAB Blog
Biosimilars Blog
RF 360

Publications

Precise. Insightful. Skilled.
Search Publications
View All

Publications

SCOTUS Affirms in Helsinn v. Teva On-Sale Bar Case

On January 22, 2019, the Supreme Court of the United States issued its opinion, authored by Justice Thomas, in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., et al., No. 17-1229, 586 U.S. __, slip…
More

New 101 Guidelines Give Applicants Two Bites at the Apple at Step 2A

On January 7, 2019, the United States Patent and Trademark Office (USPTO) published its “2019 Revised Patent Subject Matter Eligibility Guidance” (“Guidance”) in an effort to provide more consistency and predictability in the analysis of…
More

  • Get Real: Protecting Fictional Brands

    Rothwell Figg attorneys Leo M. Loughlin and Davide F. Schiavetti published an article titled "Get real: protecting fictional brands," in World Trademark Review, published by Globe Business Media Group – IP Division. The article discusses…
    More

  • New EU Patent Guidelines May Affect Companies' AI Strategy

    Innovators in artificial intelligence and machine learning technologies should take note of the European Patent Office’s recently published guidelines for artificial intelligence and machine learning, effective Nov. 1, 2018.[1] The guidelines appear to embrace an application-specific…
    More

  • Trends in Biosimilars

    Rothwell Figg attorney Aydin H. Harston participated in a roundtable titled "Trends in Biosimilars" for the October 2018 issue of Financier Worldwide Magazine. As the multi-billion dollar biosimilar market grows, Mr. Harston and others discuss the main trends emerging…
    More

  • View All Publications
Biosimilars Blog

BiosimilarsIP.com features articles, updates, and analysis on regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA). The posts, authored and edited by attorneys in the firm’s Biologics and Biosimilars practice group, track regulatory issues and events, provide analysis of legal decisions from federal courts and from the Patent Trial and Appeal Board, and offer updates on current news and events related to biologics and biosimilars. Our team understands the manufacturing, regulatory, and legal requirements of the field, and has the experience and the technical knowledge to handle the most sophisticated matters, including issues related to regulatory approval, securing patent rights, counseling and opinions, post-grant challenges, and asserting or defending against patents in litigation. To learn more, please visit www.BiosimilarsIP.com.

Visit Blog
PTAB Blog

Authored and edited by attorneys in the firm’s Post-Grant Trial practice group, PTABLaw.com provides updates, articles, and analysis about the Patent Trial and Appeal Board (PTAB), the Court of Appeals for the Federal Circuit, and the American Invents Act.  Our group has considerable experience handling inter partes review (IPR), covered business method (CBM) review, and post-grant review (PGR) proceedings before the PTAB.  Our depth of knowledge and expertise with handling matters before the PTAB is unique, as many of the attorneys in our group have substantial experience in handling interference proceedings and reexaminations, and in prosecuting applications before the Office, as well as extensive litigation experience in the federal courts. To learn more, please visit www.PTABLaw.com.

Visit Blog